Drugs targeting a specific protein could make for powerful treatments for chronic pain, according to a new study. Even diet might have an effect https://t.co/nBq9Wgd2Jr ...

I always learn from SpaceX. So the company that I deeply admire and of course you know I have Elon's picture everywhere when I whenever I think that I'm working too hard I'm looking at this picture and I realize that I'm slacking. Look at how they're building rockets.So you have the Falcon series that works extremely well. So you get the payload to the to the to to the to to to orbit and beyond and it works but at the same time you are working on Starship right and you are working on next generation Starshi ...

Company Performance - Abbott's stock closed at $132.02, reflecting a -1.18% change from the previous day, underperforming the S&P 500's daily loss of 0.33% [1] - Prior to the latest trading session, Abbott's shares had decreased by 2.09%, lagging behind the Medical sector's loss of 0.32% and the S&P 500's gain of 4.07% [1] Earnings Expectations - Abbott is set to release its earnings on July 17, 2025, with an expected EPS of $1.25, indicating a 9.65% growth year-over-year [2] - The consensus estimate for Abbott's revenue is $11.07 billion, representing a 6.7% increase compared to the same quarter last year [2] Full Year Projections - Analysts expect Abbott to achieve earnings of $5.16 per share and revenue of $44.7 billion for the full year, marking changes of +10.49% and +6.56% respectively from the previous year [3] - Recent revisions to analyst estimates suggest positive near-term business trends, indicating a favorable outlook for Abbott [3] Valuation Metrics - Abbott currently has a Forward P/E ratio of 25.91, which is a premium compared to the industry average Forward P/E of 20.14 [5] - The company holds a PEG ratio of 2.54, higher than the industry average PEG ratio of 2.29 [6] Industry Context - Abbott operates within the Medical - Products industry, which has a Zacks Industry Rank of 156, placing it in the bottom 37% of over 250 industries [6] - The strength of individual industry groups is measured by the Zacks Industry Rank, with the top 50% rated industries outperforming the bottom half by a factor of 2 to 1 [7]

Trade Policy on Pharmaceuticals - Tariffs of 200% will be imposed on pharmaceuticals brought into the country after a grace period of approximately one year to one and a half years [1] - The policy aims to address the departure of pharmaceutical companies to other locations [2] Trade Policy on Metals and Other Goods - Steel and aluminum tariffs are set at 50% [2] - Lumber tariffs have recently been implemented [2] - Copper tariffs are also set at 50% [2][3] - Tariffs have been implemented on cars [2] Expansion of Trade Policy - The company will announce policies related to pharmaceuticals, chips, and other significant sectors [2]

Pharmaceutical Policy - The government plans to announce new pharmaceutical policies soon [1] - A grace period of approximately one to one and a half years will be granted to pharmaceutical companies [1] - After the grace period, a tariff of 200% will be imposed on imported pharmaceuticals [1] Industry Impact - Pharmaceutical companies previously present in the country have relocated [1][2] - The relocation of pharmaceutical companies is attributed to previous policies [2]

Core Insights - Investing in stocks based on valuation metrics, particularly the price-to-sales (P/S) ratio, is a strategic approach for evaluating companies, especially those that are unprofitable or in early growth stages [1][3][5] Group 1: Price-to-Sales Ratio - The price-to-sales ratio is a valuable metric that reflects how much investors pay for each dollar of revenue generated by a company [3] - A P/S ratio below 1 indicates a good bargain, as investors pay less than a dollar for a dollar's worth of revenue [4] - The P/S ratio is often preferred over the price-to-earnings ratio due to the difficulty of manipulating sales figures compared to earnings [5] Group 2: Screening Parameters - Companies should have a price-to-sales ratio less than the median for their industry, along with a price-to-earnings ratio below the industry median [7] - A debt-to-equity ratio less than the industry median is also recommended, as lower debt levels contribute to a stable P/S ratio [8] - Stocks should be trading at a minimum price of $5 and have a Zacks Rank of 1 (Strong Buy) or 2 (Buy) to ensure better performance [8] Group 3: Company Profiles - Green Dot (GDOT) is a pro-consumer bank holding company with a strong position in prepaid cards and Banking-as-a-Service, boasting a Zacks Rank 1 and a Value Score of A [10][11] - JAKKS Pacific (JAKK) has diversified through acquisitions and focuses on online retailing, currently holding a Zacks Rank 2 and a Value Score of A [12][13] - PCB Bancorp (PCB) offers a range of banking products and has a strategic expansion plan, with a Value Score of A and a Zacks Rank 2 [14][15] - Gibraltar Industries (ROCK) focuses on operational improvements and has a Value Score of B with a Zacks Rank 2, benefiting from high demand in agricultural facilities [16][17] - Pfizer (PFE) is committed to developing treatments across various therapeutic areas and expects better non-COVID operational revenue growth, holding a Value Score of A and a Zacks Rank 2 [18][19]